Literature DB >> 27293806

The SCOPE of definitive chemoradiotherapy in locally advanced esophageal cancer: what direction for the future?

Gilles Créhange1, Thierry Conroy1.   

Abstract

Entities:  

Year:  2016        PMID： 27293806      PMCID： PMC4886021          DOI： 10.21037/jtd.2016.03.74

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  22 in total

1.  A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer.

Authors:  J A Ajani; L Xiao; J A Roth; W L Hofstetter; G Walsh; R Komaki; Z Liao; D C Rice; A A Vaporciyan; D M Maru; J H Lee; M S Bhutani; A Eid; J C Yao; A P Phan; A Halpin; A Suzuki; T Taketa; P F Thall; S G Swisher
Journal:  Ann Oncol       Date:  2013-08-23       Impact factor: 32.976

2.  Reduction of heart volume during neoadjuvant chemoradiation in patients with resectable esophageal cancer.

Authors:  Nadia Haj Mohammad; Martijn Kamphuis; Maarten C C M Hulshof; Lotte J Lutkenhaus; Suzanne S Gisbertz; Jacques J G H M Bergman; H A C M Rianne de Bruin-Bon; Elisabeth D Geijsen; Arjan Bel; S Mathijs Boekholdt; Hanneke W M van Laarhoven
Journal:  Radiother Oncol       Date:  2015-01-24       Impact factor: 6.280

3.  Targeted therapy and chemoradiotherapy in oesophageal cancer.

Authors:  Bryan H Burmeister; Sandro V Porceddu
Journal:  Lancet Oncol       Date:  2013-04-25       Impact factor: 41.316

4.  Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials.

Authors:  Vera Oppedijk; Ate van der Gaast; Jan J B van Lanschot; Pieter van Hagen; Rob van Os; Caroline M van Rij; Maurice J van der Sangen; Jannet C Beukema; Heidi Rütten; Patty H Spruit; Janny G Reinders; Dick J Richel; Mark I van Berge Henegouwen; Maarten C C M Hulshof
Journal:  J Clin Oncol       Date:  2014-01-13       Impact factor: 44.544

5.  Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.

Authors:  Thierry Conroy; Marie-Pierre Galais; Jean-Luc Raoul; Olivier Bouché; Sophie Gourgou-Bourgade; Jean-Yves Douillard; Pierre-Luc Etienne; Valérie Boige; Isabelle Martel-Lafay; Pierre Michel; Carmen Llacer-Moscardo; Eric François; Gilles Créhange; Meher Ben Abdelghani; Beata Juzyna; Laurent Bedenne; Antoine Adenis
Journal:  Lancet Oncol       Date:  2014-02-18       Impact factor: 41.316

6.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

7.  Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer.

Authors:  Steven H Lin; Lu Wang; Bevan Myles; Peter F Thall; Wayne L Hofstetter; Stephen G Swisher; Jaffer A Ajani; James D Cox; Ritsuko Komaki; Zhongxing Liao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-08-03       Impact factor: 7.038

8.  Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.

Authors:  Thomas Crosby; Christopher N Hurt; Stephen Falk; Simon Gollins; Somnath Mukherjee; John Staffurth; Ruby Ray; Nadim Bashir; John A Bridgewater; J Ian Geh; David Cunningham; Jane Blazeby; Rajarshi Roy; Tim Maughan; Gareth Griffiths
Journal:  Lancet Oncol       Date:  2013-04-25       Impact factor: 41.316

9.  Intensity modulated radiotherapy (IMRT) with concurrent chemotherapy as definitive treatment of locally advanced esophageal cancer.

Authors:  Falk Roeder; Nils H Nicolay; Tam Nguyen; Ladan Saleh-Ebrahimi; Vasilis Askoxylakis; Tilman Bostel; Felix Zwicker; Juergen Debus; Carmen Timke; Peter E Huber
Journal:  Radiat Oncol       Date:  2014-08-29       Impact factor: 3.481

10.  Dosimetric benefits of IMRT and VMAT in the treatment of middle thoracic esophageal cancer: is the conformal radiotherapy still an alternative option?

Authors:  Zhiqin Wu; Congying Xie; Meilong Hu; Ce Han; Jinling Yi; Yongqiang Zhou; Huawei Yuan; Xiance Jin
Journal:  J Appl Clin Med Phys       Date:  2014-05-08       Impact factor: 2.102
View more
  1 in total

1.  Impact of Age and Comorbidity on Choice and Outcome of Two Different Treatment Options for Patients with Potentially Curable Esophageal Cancer.

Authors:  Z Faiz; M van Putten; R H A Verhoeven; J W van Sandick; G A P Nieuwenhuijzen; M J C van der Sangen; V E P P Lemmens; B P L Wijnhoven; J T M Plukker
Journal:  Ann Surg Oncol       Date:  2019-02-04       Impact factor: 5.344
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.